Fig. 2

TP-0903 treatment suppresses the population of CD206⁺ macrophages in human IBC xenograft and murine TNBC syngeneic models. A Tumors from a SUM149 xenograft mouse model treated with vehicle or TP-0903 for 7 days were dissociated to obtain a single-cell suspension and stained with antibodies. Flow cytometric analysis showed a decreased CD206⁺ macrophage population (CD45⁺CD11b⁺Ly6C⁻Ly6G⁻F4/80⁺CD206⁺ cells) after TP-0903 treatment. B IHC staining of CD206 on slides from the above tumor sections. TP-0903 decreased the population of CD206⁺ cells in SUM149 tumor tissues. Left panel: representative IHC staining images. Scale bar = 200 μm. Right panel: quantification of CD206 expression by ImageJ. C Tumor growth curves for the vehicle- and TP-0903–treated groups in murine TNBC syngeneic mouse models. TP-0903 suppressed the growth of 4T1.2 and E0771 mammary tumors in vivo. D TP-0903 treatment reduced CD206⁺ macrophages in murine mammary tumors from the 4T1.2 mouse model. E IHC staining for CD206 showed reduced CD206⁺ cells in TP-0903–treated tumor tissues from E0771 mice. Left panel: representative IHC staining images. Scale bar = 200 μm. Right panel: quantification of CD206 expression. F Flow cytometric analysis showed a decrease in Tregs (CD45⁺CD3⁺CD4⁺CD25⁺FOXP3⁺ cells) in TP-0903–treated 4T1.2 and E0771 mice. 4T1.2 syngeneic model: n = 10 mice; E0771 syngeneic model: n = 15 mice. Data were summarized as means ± SD in A, B, and D to F and means ± SEM in C. A 2-tailed Student t test was used to calculate P values. *P < 0.05; **P < 0.01